Among 6,609 participants, 46% had diabetes (96.4% with type 2 diabetes mellitus), and approximately 31% had DKD [48]
The pharmacy benefit manager Prime Therapeutics published an analysis last summer that highlights this ongoing challenge with respect to the real-world effectiveness over time of the GLP-1 drugs used to treat obesity: Most overweight or obese patients without diabetes stop treatment within the first few years
GLP-1 receptor agonists and risk of hepatocellular carcinoma and all-cause mortality in patients with MASLD and type 2 diabetes: a propensity score-matched population-based cohort study
Taking Topamax with valproic acid (Depakene) or a similar divalproex sodium drug (Depakote) has links to hypothermia and hyperammonemia
The FDA has warned against turning to a compounding pharmacy for generic versions of semaglutide, the active ingredient in Ozempic and Wegovy, because of unanticipated side effects
While it does offer numerous health benefits, its important to be aware of its potential side effects before adding it to your regimen